Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in extracutaneous lymphomas.

A Chott1, M Raderer

  • 1Department of Clinical Pathology, University of Vienna, Austria.

Seminars in Cutaneous Medicine and Surgery
|July 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Endocrine-related cancer·2024
Same author

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Localised Synovial Sarcoma in Adolescents and Young Adults Versus Adults - Is There a Difference in Outcome?

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study.

Epidemiology and psychiatric sciences·2022
Same author

Corrigendum to 'How I treat medullary thyroid cancer': [ESMO Open Volume 6, Issue 3, June 2021, 100183].

ESMO open·2022

The World Health Organization classification guides lymphoma diagnosis, incorporating clinical data and molecular insights. Most B-cell lymphomas originate from germinal center B cells, with specific genetic alterations impacting prognosis and treatment.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The World Health Organization (WHO) classification of lymphoid neoplasms builds upon the 1994 Revised European-American Classification.
  • Lymphoma diagnosis now emphasizes clinical data, particularly the site of involvement (nodal vs. extranodal).
  • Advances in molecular biology offer new insights into the cellular origins of B-cell lymphomas.

Purpose of the Study:

  • To review the updated WHO classification of lymphoid neoplasms.
  • To highlight molecular insights into the pathogenesis of non-Hodgkin's lymphomas (NHL).
  • To discuss the clinical and prognostic implications of recent discoveries.

Main Methods:

  • Review of current literature and classification systems.
  • Analysis of molecular biological investigations at the single-cell level.

Related Experiment Videos

  • Integration of clinical data with pathological findings.

    • Main Results:

    • The majority of B-cell non-Hodgkin's lymphomas (NHL) and Hodgkin's disease are derived from germinal center B cells.
    • Key molecular findings include the B-CLL dichotomy, 3q27 translocations in diffuse large B-cell lymphomas (DLBCL), t(2;5) in anaplastic large cell lymphoma, and t(11;18) in gastric MALT lymphoma.
    • A causal link between Helicobacter pylori infection and gastric MALT lymphoma has been established.

    Conclusions:

    • The WHO classification represents a significant advancement in lymphoma diagnosis and understanding.
    • Molecular pathogenesis studies are crucial for defining prognostic markers and therapeutic targets.
    • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy remains the standard treatment for DLBCL.